Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

Arthritis and Rheumatism

Volumn 43, Issue 7, 2000, Pages 1431-1442

  Ioannou, Yiannis ^a   Isenberg, David A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Centre for Rheumatology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNE DISEASE; DRUG INDICATION; DRUG INDUCED DISEASE; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE;

ARTHRITIS, RHEUMATOID; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; NEOPLASMS;

EID: 0033938967     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E     Document Type: Review

References (109)

1. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology 1993;18:1300-5.
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B c antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
3. Vugrin D, Hood L, Taylor W, Laszlo J. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma. Cancer Treat Rep 1985;69:817-20.
4. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15-8.
5. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314: 1065-9.
6. Schlag R, Flieger D, Ziegler-Heitbrock HW, Hill W, Emmerich B, Thiel E. Interferon alfa-2B in chronic lymphatic leukemia of the B-cell type. Dtsch Med Wochenschr 1990;115:1088-95.
7. Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986;67:275-8.
8. Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984;311:1148-52.
9. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309:129-33.
10. Eriksson B, Oberg K, Alm G, Karlsson A, Lundqvist G, Andersson T, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 1986;2:1307-9.
11. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, O'Fallon JR, et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984;2:1002-5.
12. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
13. Krown SE, Real FX, Cunningham-Rundles S, Myskowski PL, Koziner B, Fein S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6.
14. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318: 1557-63.
15. Bernstein RM. Rheumatic complications of drugs and toxins. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford textbook of rheumatology. 2nd ed. Oxford: Oxford University Press; 1998. p. 1692.
16. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
17. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992;327:28-35.
18. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16.
19. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
20. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
21. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
22. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7.
23. Vanderpump MPJ, Tunbridge WMG. The epidemiology of thyroid disease. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's the thyroid - a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven; 1966. p. 474-82.
24. Tolaymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992;120:429-32.
25. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68:1536-7.
26. Flores A, Olivé A, Feliu E, Tena X. Systemic lupus erythematosus following interferon therapy [letter]. Br J Rheumatol 1994; 33:787.
27. Conlon KC, Urba WJ, Smith JWD, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990;65:2237-42.
28. Silman AJ. Epidemiology and rheumatic diseases. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford textbook of rheumatology. 2nd ed. Oxford: Oxford University Press: 1998. p. 811-28.
29. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992;65:70-4.
30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
31. Ehrenstein MR, McSweeney E, Swane M, Worman CP, Goldstone AH, Isenberg DA. Appearance of anti-DNA antibodies in patients treated with interferon-α. Arthritis Rheum 1993;36:279-80.
32. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998;91:393-9.
33. Cosserat J, Cacoub P, Bletry O. Immunological disorders in C virus chronic hepatitis. Nephrol Dial Transplant 1996;11 Suppl 4:31-5.
34. Pittau E, Bogliolo A, Tinti A, Mela Q, Ibba G, Salis G, et al. Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Clin Exp Rheumatol 1997;15:415-9.
35. Cleveland MG, Mallory SB. Incomplete Reiter's syndrome induced by systemic interferon alpha treatment. J Am Acad Dermatol 1993;29:788-9.
36. Makino Y, Tanaka H, Nakamura K, Fujita M, Akiyama K, Makino I. Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C. J Rheumatol 1994;21: 1771-2.
37. Kiely PD, Bruckner FE. Acute arthritis following interferon-alpha therapy. Br J Rheumatol 1994;33:502-3.
38. Chan GC, Lee SS, Yeoh EK. Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment. J Gastroenterol Hepatol 1992;7:432-3.
39. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;70:562-9.
40. Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 1986;63:450-8.
41. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994;88:268-74.
42. Rose LM, Latchman DS, Isenberg DA. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br J Rheumatol 1997;36:158-63.
43. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 1991;88:8661-5.
44. Aringer M, Wintersberger W, Steiner CW, Kiener H, Presterl E, Jaeger U, et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1423-30.
45. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA, SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. QJM 1990;74:319-30.
46. Kirou KA, Vakkalanka RK, Butler MJ, Crow MK. Interferon-A induces FasL on peripheral blood mononuclear cells and killing of Fas-sensitive cells [abstract]. Arthritis Rheum 1998;41 Suppl 9:S36.
47. Cheng J, Liu C, Yang P, Zhou T, Mountz JD. Increased lymphocyte apoptosis in Fas ligand transgenic mice. J Immunol 1997;159:674-84.
48. Rose LM, Latchman DS, Isenberg DA. Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 1997;6:717-22.
49. De Maeyer E, De Maeyer-Guignard J. Type I interferons. Int Rev Immunol 1998;17:53-73.
50. Schattner A, Duggan D, Naparstek Y, Schwartz RS. Effects of interferon-alpha on the expression of a lupus idiotype in normal humans. Clin Immunol Immunopathol 1986;38:327-36.
51. Knop J, Taborski B, DeMaeyer-Guignard J. Selective inhibition of the generation of T suppressor cells of contact sensitivity in vitro by interferon. J Immunol 1987;138:3684-7.
52. Duncan MR, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987;79:1318-24.
53. Kahari V-M, Hieno J, Vuorio J, Vuorio E. Interferons α and γ reduce excessive collagen synthesis and procollagen mRNA levels in systemic sclerosis fibroblasts in culture. Biochem Biophys Acta 1998;968:45-50.
54. Miossec P. Cytokine-induced autoimmune disorders. Drug Saf 1997;17:93-104.
55. Veys EM, Menkes C-J, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997;40:62-8.
56. Kiely PD. The Th1-Th2 model - what relevance to inflammatory arthritis? Ann Rheum Dis 1998;57:328-30.
57. Roitt I, Brostoff J, Male D. Cell co operation in antibody response. In: Immunology. 5th ed. London: Mosby; 1998. p. 139-53.
58. Lissoni P, Barni S, Cattaneo G, Archili C, Crispino S, Tancini G, et al. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int J Biol Markers 1990;5:195-7.
59. Weijl NI, van der Harst D, Brand A, Kooy Y, van Luxemburg S, Schroder J, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993;11:1376-83.
60. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999;17:529-33.
61. Massarotti EM, Liu NY, Mier J, Atkins MB. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992;92:693-7.
62. Scheibenbogen C, Keilholz U, Pezzutto A, Hunstein W. Rheumatic disease following immunotherapy [letter]. Ann Rheum Dis 1993;52:165.
63. Corrigall VM, Arastu M, Khan S, Panayi GS. Stimulation of MCP-1 production by synovial fibroblasts following activation with IL-2 and IL-15 and T cell contact [abstract]. Arthritis Rheum 1998;41 Suppl 9:S297.
64. Hachicha M, Rathanaswami P, Schall TJ, McColl SR. Production of monocyte chemotactic protein-1 in human type B synoviocytes: synergistic effect of tumor necrosis factor α and interferon-γ. Arthritis Rheum 1993;36:26-34.
65. Esteva-Lorenzo FJ, Janik JE, Fenton RG, Emslie-Smith A, Engel AG, Longo DL. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 1995;76: 1219-23.
66. Finger DR, Dennis GJ. Focal myositis. J Rheumatol 1995;22: 188-9.
67. Ytterberg SR, Roelofs RI, Mahowald ML. Inclusion body myositis and renal cell carcinoma: report of two cases and review of the literature. Arthritis Rheum 1993;36:416-21.
68. Wolf RE, Baethge BA. Interleukin-1 α, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990;33: 1007-14.
69. Puett DW, Fuchs HA. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma. J Rheumatol 1994;21:752-3.
70. Famularo G, Procopio A, Giacomelli R, Danese C, Sacchetti S, Perego MA, et al. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990;81:368-72.
71. Kahaleh MB, LeRoy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989;110:446-50.
72. Umehara H, Kumagai S, Ishida H, Suginoshita T, Maeda M, Imura H. Enhanced production of interleukin-2 in patients with progressive systemic sclerosis: hyperactivity of CD4-positive T cells? Arthritis Rheum 1988;31:401-7.
73. Devajyothi C, Kalvakolanu I, Babcock GT, Vasavada HA, Howe PH, Ransohoff RM. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells: definition of cis-element. J Biol Chem 1993;268:18794-800.
74. Notonha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-53.
75. Levesque MC, Ward FE, Jeffery DR, Weinberg JB. Interferon-β1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Arthritis Rheum 1999;42:569-73.
76. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997;26:689-701
77. Midgard R, Gronning M, Riise T, Kvale G, Nyland H. Multiple sclerosis and chronic inflammatory diseases: a case-control study. Acta Neurol Scand 1996;93:322-8.
78. Alsalameh S, Manger B, Kern P, Kalden J. New onset of rheumatoid arthritis during interferon β-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson [letter]. Arthritis Rheum 1998;41:754.
79. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120-6.
80. Jabaily JA, Thompson JS. Effects of interferon β· 1B in rheumatoid arthritis: a case report [letter]. Arthritis Rheum 1947;40: 1370.
81. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum 1999;42:90-9.
82. Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 1994;97:459-67.
83. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33: 305-15.
84. Machold KP, Neumann K, Smolen JS. Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 1992;51: 1039-43.
85. Veys FM, Mielants H, Verbruggen G, Grosclaude JP, Meyer W, Galazka A, et al. Interferon gamma in rheumatoid arthritis - a double blind study comparing human recombinant interferon gamma with placebo. J. Rheumatol 1988;15:570-4.
86. Kung AW, Jones BM, Lai CL. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinol Metab 1990;71: 1230-4.
87. Seitz M, Franke M, Kirchner H. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma. Ann Rheum Dis 1988;47:642-4.
88. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jahkowski J, MacHeiner W, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998;139:639-48.
89. Machold KP, Smolen JS. Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 1990;17: 831-2.
90. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Ziclinski CC, Smolen JS. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991;18:1621-2.
91. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987;166:798-803.
92. Seety JP, Carroll JM, Cattell V, Watt FM. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 1997;186:1451-9.
93. Richards HB, Shaheen VM, Satoh M, Reeves WH. Cytokine requirements differ for anti-DNA/chromatin and nRNP/Sm autoantibodies [abstract]. Arthritis Rheum 1998;41 Suppl 9:S128.
94. Stephanou A, Isenberg DA, Nakajima K, Latchman DS. Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem 1999;274:1723-8.
95. Koshiji M, Adachi Y, Sogo S, Taketani S, Oyaizu N, Than S, et al. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression. Clin Exp Immunol 1998;111:211-8.
96. Hazenberg BP, van Leeuwen MA, van Rijswijk MH, Stern AC, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor: simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1489;74:2769-70.
97. Yasuda M, Kihara T, Wada T, Shiokawa S, Furuta E, Suenagu Y, et al. Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty's syndrome patient. Arthritis Rheum 1994;37:145-6.
98. Vidarsson B, Geirsson AJ, Onundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am J Med 1995;98:589-91.
99. De Vries EG, Willemse PH, Biesma B, Stern AC, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991;338:517-8.
100. Hoshina Y, Moriuchi J, Nakamura Y, Arimori S, Ichikawa Y. CD4+ T cell-mediated leukopenia of Felty's syndrome successfully treated with granulocyte-colony-stimulating factor and methotrexate. Arthritis Rheum 1994;37:298-9.
101. Rankin ECC, Choy EHS, Ehrenstein MR, Ravirajan CT, Sopwith M, Vetterlein O, et al. Serological effects of repeated doses of an engineered human anti-TNFa antibody, CDP571, in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1995;38 Suppl 9:S279.
102. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
103. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996;25: 972-5.
104. Finger DR, Plotz PH, Heywood G. Myositis following treatment with high dose interleukin-2 for malignancy [letter]. J Rheumatol 1995;22:2188.
105. Prussick R, Plott RT, Stanley JR. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy. Arch Dermatol 1994;130:890-3.
106. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-96.
107. Puduvalli VK, Sella A, Austin SG, Forman AD. Carpal tunnel syndrome associated with interleukin-2 therapy. Cancer 1996;77: 1189-92.
108. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.
109. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-5.